Abstract:Since the report of "DNA untwisting" activity in 1972, ~50 years of research has revealed seven topoisomerases in humans (TOP1, TOP1mt, TOP2α, TOP2β, TOP3α, TOP3β and Spo11). These conserved regulators of DNA topology catalyze controlled breakage to the DNA backbone to relieve the torsional stress that accumulates during essential DNA transactions including DNA replication, transcription, and DNA repair. Each topoisomerase-catalyzed reaction involves the formation of a topoisomerase cleavage complex (TOPcc), a covalent protein-DNA reaction intermediate formed between the DNA phosphodiester backbone and a topoisomerase catalytic tyrosine residue. A variety of perturbations to topoisomerase reaction cycles can trigger failure of the enzyme to re-ligate the broken DNA strand(s), thereby generating topoisomerase DNA-protein crosslinks (TOP-DPC). TOP-DPCs pose unique threats to genomic integrity. These complex lesions are comprised of structurally diverse protein components covalently linked to genomic DNA, which are bulky DNA adducts that can directly impact progression of the transcription and DNA replication apparatus. A variety of genome maintenance pathways have evolved to recognize and resolve TOP-DPCs. Eukaryotic cells harbor tyrosyl DNA phosphodiesterases (TDPs) that directly reverse 3′-phosphotyrosyl (TDP1) and 5′-phoshotyrosyl (TDP2) protein-DNA linkages. The broad specificity Mre11-Rad50-Nbs1 and APE2 nucleases are also critical for mitigating topoisomerase-generated DNA damage. These DNA-protein crosslink metabolizing enzymes are further enabled by proteolytic degradation, with the proteasome, Spartan, GCNA, Ddi2, and FAM111A proteases implicated thus far. Strategies to target, unfold, and degrade the protein component of TOP-DPCs have evolved as well. Here we survey mechanisms for addressing Topoisomerase 1 (TOP1) and Topoisomerase 2 (TOP2) DPCs, highlighting systems for which molecular structure information has illuminated function of these critical DNA damage response pathways.

Bioinformatic Analysis of Topoisomerase IIα Reveals Interdomain Interdependencies and Critical C-Terminal Domain Residues

Post-translational modifications in DNA topoisomerase 2α highlight the role of a eukaryote-specific residue in the ATPase domain

Physiological regulation of eukaryotic topoisomerase II

Modeling Allosteric Mechanisms of Eukaryotic Type II Topoisomerases

Phosphorylation of Serine 1106 in the Catalytic Domain of Topoisomerase IIα Regulates Enzymatic Activity and Drug Sensitivity

Crystal Structures, Molecular Docking and In Vitro Investigations of Two 4-Substituted 2-(5,5-dimethyl-3-styrylcyclohex-2-enylidene)malononitrile Derivatives as Potential Topoisomerase II Inhibitors

Consistent rationalization of type-2 topoisomerases' unknotting, decatenating, supercoil-relaxing actions and their scaling relation.

Evolutionary Trace Analysis of Eukaryotic DNA Topoisomerase I Superfamily: Identification of Novel Antitumor Drug Binding Site

Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.

From the TOP: Formation, Recognition and Resolution of Topoisomerase DNA Protein Crosslinks

Topoisomerase IIb binding underlies frequently mutated elements in cancer genomes

Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

Type II topoisomerases shape multi-scale 3D chromatin folding in regions of positive supercoils

Topoisomerase IIα in Chromosome Instability and Personalized Cancer Therapy

Identification of novel topoisomerase II alpha inhibitors by virtual screening, molecular docking, and bioassay

Crystal structure of the N-terminal region of human Topoisomerase IIβ binding protein 1.

Topoisomerase IIβ targets DNA crossovers formed between distant homologous sites to modulate chromatin structure and gene expression

Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene.

Identification of potent catalytic inhibitors of human DNA topoisomerase II by structure-based virtual screening.

Topoisomerase IIβ targets DNA crossovers formed between distant homologous sites to induce chromatin opening

Topoisomerase IIalpha controls the decatenation checkpoint.